JP2015505245A - 川崎病のためのバイオマーカー - Google Patents

川崎病のためのバイオマーカー Download PDF

Info

Publication number
JP2015505245A
JP2015505245A JP2014550413A JP2014550413A JP2015505245A JP 2015505245 A JP2015505245 A JP 2015505245A JP 2014550413 A JP2014550413 A JP 2014550413A JP 2014550413 A JP2014550413 A JP 2014550413A JP 2015505245 A JP2015505245 A JP 2015505245A
Authority
JP
Japan
Prior art keywords
pdgfc
expression
subject
rna
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014550413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505245A5 (enExample
Inventor
バージニア エム． パスクアル
バージニア エム． パスクアル
チャオホイ スー
チャオホイ スー
オクタビオ ラミーロ
オクタビオ ラミーロ
ローランド チマズ
ローランド チマズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of JP2015505245A publication Critical patent/JP2015505245A/ja
Publication of JP2015505245A5 publication Critical patent/JP2015505245A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/49—Platelet-derived growth factor [PDGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
JP2014550413A 2011-12-29 2012-12-21 川崎病のためのバイオマーカー Pending JP2015505245A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161581199P 2011-12-29 2011-12-29
US61/581,199 2011-12-29
PCT/US2012/071360 WO2013101758A1 (en) 2011-12-29 2012-12-21 Biomarkers for kawasaki disease

Publications (2)

Publication Number Publication Date
JP2015505245A true JP2015505245A (ja) 2015-02-19
JP2015505245A5 JP2015505245A5 (enExample) 2016-02-12

Family

ID=47459205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014550413A Pending JP2015505245A (ja) 2011-12-29 2012-12-21 川崎病のためのバイオマーカー

Country Status (7)

Country Link
US (1) US20140348818A1 (enExample)
EP (1) EP2798081A1 (enExample)
JP (1) JP2015505245A (enExample)
KR (1) KR20140108718A (enExample)
CN (1) CN104160039B (enExample)
CA (1) CA2862270A1 (enExample)
WO (1) WO2013101758A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502541A (ja) * 2016-11-11 2020-01-23 アセンダント ディーエックス， エルエルシー 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3137907A4 (en) * 2014-05-02 2018-02-28 Momenta Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of kawasaki disease
CN104450901B (zh) * 2014-11-27 2016-09-21 广州赛哲生物科技股份有限公司 快速诊断川崎病的核酸标记物及其试剂盒
JP6153239B2 (ja) * 2015-02-10 2017-06-28 公立大学法人横浜市立大学 川崎病の検査方法およびキット
CN105112552B (zh) * 2015-09-28 2018-02-27 北京泱深生物信息技术有限公司 Ift52基因在骨质疏松症诊断中的应用
CN106636413B (zh) * 2016-12-28 2019-07-16 常州市第二人民医院 一种用于诊断哮喘的分子标志物
CN106701962B (zh) * 2016-12-28 2020-07-28 广州赛哲生物科技股份有限公司 用于川崎病检测的引物组、探针及试剂盒
CN110824173B (zh) * 2019-11-27 2022-09-02 中国人民解放军陆军军医大学第一附属医院 促血管生成因子pdgfc在作为诊断和治疗肝肺综合征的标志物中的应用
WO2025077406A1 (zh) * 2023-10-11 2025-04-17 中国医学科学院北京协和医院 一种新生物标志物在诊断或辅助诊断spn中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5286623A (en) * 1991-11-26 1994-02-15 National Jewish Center For Immunology And Respiratory Medicine Method for screening for Kawasaki disease
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
ATE507240T1 (de) * 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
SG157299A1 (en) * 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2010025393A2 (en) 2008-08-28 2010-03-04 The Regents Of The University Of California Protein biomarkers and methods for diagnosing kawasaki disease
CA2766403A1 (en) * 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6016037913; 日本臨床免疫学会会誌 Ｖｏｌ．２５，　Ｎｏ．５, 2002, ｐ．４１２ *
JPN6016037915; Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｃｅｌｌ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．３１４，　Ｎｏ．１４, 2008, ｐｐ．２５２９-２５４３ *
JPN6016037917; 小児科臨床 Ｖｏｌ．４４，　Ｎｏ．７, 1991, ｐｐ．２０４１-２０４３ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502541A (ja) * 2016-11-11 2020-01-23 アセンダント ディーエックス， エルエルシー 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法
JP2022110148A (ja) * 2016-11-11 2022-07-28 アセンダント ディーエックス， エルエルシー 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法
JP7132233B2 (ja) 2016-11-11 2022-09-06 アセンダント ディーエックス， エルエルシー 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法
US11448648B2 (en) 2016-11-11 2022-09-20 Ascendant Diagnostics, LLC Compositions and methods for diagnosing and differentiating systemic juvenile idiopathic arthritis and Kawasaki disease

Also Published As

Publication number Publication date
WO2013101758A1 (en) 2013-07-04
US20140348818A1 (en) 2014-11-27
KR20140108718A (ko) 2014-09-12
CN104160039B (zh) 2021-08-03
CN104160039A (zh) 2014-11-19
EP2798081A1 (en) 2014-11-05
CA2862270A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
CN104160039B (zh) 川崎病的生物标志物
US10017821B2 (en) Biomarkers for diagnosing ischemia
KR101222437B1 (ko) 바이오마커
Kumar et al. Association between pro-(IL-8) and anti-inflammatory (IL-10) cytokine variants and their serum levels and H. pylori-related gastric carcinogenesis in northern India
WO2012009547A2 (en) Biomarkers for diagnosis of transient ischemic attacks
CN101970689A (zh) 炎性肠病的基因表达标志物
JP6997709B2 (ja) 全身性炎症反応症候群（ｓｉｒｓ）患者における合併症リスクを評価する方法
US20200109454A1 (en) Nourin molecular biomarkers diagnose angina patients with negative troponin
WO2024041348A1 (en) Blood molecualr biomarkers and methods for diagnosis of acute kawasaki disease
JP2020513574A (ja) 疾患の診断用組成物
US20200063203A1 (en) Diagnostic markers for platelet function and methods of use
CN103562404A (zh) 预测肝癌预后的组合物或试剂盒以及预测肝癌预后的方法
KR20110135911A (ko) 바이오마커
JP6347477B2 (ja) 関節リウマチ患者に対する抗ｉｌ−６受容体抗体治療の有効性予測方法
KR20200102746A (ko) 췌장암 진단용 조성물
CN116445606A (zh) 血清分子标志物comp在辅助诊断抑郁症中的应用
WO2018202792A1 (en) Methods for the prediction of acute respiratory distress syndrome
CN114959003A (zh) 急性心肌梗死标志物及其应用
WO2020007270A1 (zh) 无创诊断心肌梗死的标志物和诊断方法
WO2024037387A1 (en) Blood biomarkers and methods for diagnosis of acute kawasaki disease
WO2019208542A1 (ja) スティル病と敗血症との鑑別用バイオマーカー
WO2024213795A1 (en) Diagnosis method using cell free nucleosome levels
JP2025142656A (ja) アベマシクリブまたはその薬学的に許容可能な塩による肝障害発現リスクの検査方法
KR20130141044A (ko) 급성 심근경색 조기 진단 마커
US8999338B2 (en) Method for diagnosis for multiple sclerosis involving anti1-receptor antibody

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170621